Status:
COMPLETED
Effects of Almond Intake on Atherogenic Lipoprotein Particles
Lead Sponsor:
UCSF Benioff Children's Hospital Oakland
Collaborating Sponsors:
Almond Board of California
Conditions:
Dyslipidemia
Obesity, Abdominal
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Increased abdominal adiposity is a key feature of metabolic syndrome, which describes a cluster of cardiovascular disease (CVD) risk factors that also includes insulin resistance, high blood pressure ...
Eligibility Criteria
Inclusion
- Age 20 or older
- Increased abdominal adiposity as defined by waist circumference ≥102 for men or ≥88 for women.
- Fasting blood sugar (FBS) \< 126 mg/dl
- Weight stable for \> 3 months.
Exclusion
- History of coronary heart disease, cerebrovascular disease, peripheral vascular disease, bleeding disorder, liver or renal disease, diabetes, lung disease, HIV, or cancer (other than skin cancer) in the last 5 years.
- Taking hormones or drugs known to affect lipid metabolism or blood pressure.
- Systolic blood pressure \> 160 mm Hg and diastolic blood pressure \> 95 mm Hg.
- Body mass index (BMI) \> 38 kg/m2
- User of nicotine products or recreational drugs
- Refusal to abstain from alcohol or dietary supplements during the study.
- Total- and LDL-C \> 95th percentile for sex and age.
- Fasting triglycerides \> 50mg/dl and \> 500 mg/dl
- Abnormal thyroid stimulating hormone (TSH) levels.
- Pregnant or breast-feeding
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01792648
Start Date
April 1 2013
End Date
April 1 2016
Last Update
November 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cholesterol Research Center
Berkeley, California, United States, 94705